ClinicalTrials.gg
CompletedNCT00051168Updated Oct 7, 2011Results posted

A Long-term Safety Study of Once-daily Travatan

A Phase 3 interventional study of Travatan in Glaucoma, Open-angle and Ocular Hypertension, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-07.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
502
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
6th of 45
502 · median 135
Started
2006
the only one that year
Phase 3
16 of 46
none open now
Registered
1st of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 6th largest by enrollment of the 45 interventional ones that give a count, is the only one that started in 2006, is one of 16 in phase 3, and was the 1st registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.

03

Conditions studied

  • Glaucoma, Open-angle
  • Ocular Hypertension

Keywords

  • Glaucoma
  • POAG
  • OAG
  • OHT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Adult patients of any race and either sex with chronic angle-closure glaucoma.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
502 participants (actual)

Study arms

  • Experimental
    Travatan

    Travoprost (0.004%)

    Drug: Travatan

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Intraocular Pressure

    Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken. All IOP measurements were performed with a Goldmann applanation tonometer.

    Time frame: At 5 years.

07

Results

Posted Apr 12, 2010

Participant flow

Patients were recruited in ophthalmic clinics, academic and civil hospitals from September 24, 2002. Last patient completed the study on March 23, 2009.

Participant flow — Overall Study
MilestoneTravatan
Started502
Completed367
Not completed135

Outcome measures

PrimaryMean Intraocular Pressure

Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken. All IOP measurements were performed with a Goldmann applanation tonometer.

Time frame:
At 5 years.
Reported as:
Mean · millimeters mercury (mm Hg)
Mean Intraocular Pressure
millimeters mercury (mm Hg)Travatan
Mean Intraocular Pressure16.5 ± 2.6

Adverse events

Collected over Baseline to 5 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Travatan—99/502 (19.7%)304/502 (60.6%)
Most frequent serious events
Showing 10 of 96
Most frequent serious events
EventTravatan
InjuryInjury, poisoning and procedural complications8/502
PneumoniaInfections and infestations4/502
OsteoarthritisMusculoskeletal and connective tissue disorders4/502
Myocardial infarctionCardiac disorders3/502
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/502
Cerebrovascular accidentNervous system disorders3/502
CholecystectomySurgical and medical procedures3/502
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/502
Cardio-respiratory arrestCardiac disorders2/502
Respiratory tract infectionInfections and infestations2/502
Most frequent other events
Most frequent other events
EventTravatan
Iris hyperpigmentationEye disorders148/502
CataractEye disorders147/502
HypertensionVascular disorders83/502
Visual acuity reducedEye disorders55/502
Ocular hyperemiaEye disorders50/502
HypercholesterolaemiaMetabolism and nutrition disorders38/502
Diabetes mellitusMetabolism and nutrition disorders26/502
InjuryInjury, poisoning and procedural complications25/502
Dry eyeEye disorders25/502

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Travatan
<=18 years0
Between 18 and 65 years237
>=65 years265
Sex: Female, Male
Sex: Female, Male(Participants)Travatan
Female281
Male221
08

Study locations

1 site
  • Europe
    Fort Worth, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006 and a primary completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2003
First posted
Jan 7, 2003
Start
Jan 2006
Primary completionActual
Mar 2009
Results first posted
Apr 12, 2010
Last update
Oct 7, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00051168
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Jan 7, 2003
Start date
Jan 2006
Primary completion
Mar 2009
Results posted
Apr 12, 2010
Last update
Oct 7, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion